<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01408836</url>
  </required_header>
  <id_info>
    <org_study_id>BMH4-CT97-2328</org_study_id>
    <nct_id>NCT01408836</nct_id>
  </id_info>
  <brief_title>Plasma Exchange for Renal Vasculitis</brief_title>
  <acronym>MEPEX</acronym>
  <official_title>Randomised Trial of Plasma Exchange or High Dose Methyl Prednisolone as Adjunctive Therapy for Severe Renal Vasculitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London North West Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals, Leicester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lund University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundacio Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether additional therapy with plasma exchange improves
      the chances of kidney recovery in severe kidney vasculitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary systemic vasculitis associated with autoantibodies to neutrophil cytoplasmic antigens
      (ANCA), is the most frequent cause of rapidly progressive glomerulonephritis. Renal failure
      at presentation often progresses to end stage renal disease despite immunosuppressive
      therapy. We investigated whether the addition of plasma exchange was more effective than
      intravenous (IV) methyl prednisolone in the achievement of renal recovery for ANCA associated
      systemic vasculitis presenting with a serum creatinine above 500umol/l (5.8mg/dl).

      137 patients with a new diagnosis of ANCA associated systemic vasculitis, serum creatinine
      above 500umol/l (5.8mg/dl) and a renal biopsy demonstrating a focal, necrotizing
      glomerulonephritis were randomized to receive seven plasma exchanges or IV methyl
      prednisolone 1000mg/day for three days. Both groups were treated with cyclophosphamide and
      oral prednisolone. The primary end-point was dialysis independence with a serum creatinine
      below 500umol/l (5.8mg/dl) at three months. Secondary end-points included renal and patient
      survival at 12 months and severe adverse event rates.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Completed
  </why_stopped>
  <start_date>March 1995</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal recovery</measure>
    <time_frame>Three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>End stage renal disease at 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine at 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Wegener's Granulomatosis</condition>
  <condition>Microscopic Polyangiitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plasma exchange x 7 over 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methyl prednisolone 1g x 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Plasma exchange</intervention_name>
    <description>Plasma exchange</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous methyl prednisolone</intervention_name>
    <description>Intravenous methyl prednisolone</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methyl prednisolone</intervention_name>
    <description>methyl prednisolone</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Wegener's granulomatosis or microscopic polyangiitis, using criteria
             adapted by EUVAS from the disease definitions of the Chapel Hill consensus conference

          -  Biopsy proven, pauci-immune, necrotising and/or crescentic glomerulonephritis, in the
             absence of other defined glomerulopathy

          -  Severe renal impairment defined by: (i) oliguria (&lt;400ml/24hr), or (ii) intention to
             commence dialysis within 48 hours of admission, and (iii) creatinine &gt;500umol/l
             (5.8mg/dl).

        Exclusion Criteria:

          -  Age under 18 or over 80 years

          -  Inadequate contraception in women of child-bearing age

          -  Pregnancy

          -  Previous malignancy

          -  Hepatitis B antigenaemia, anti-hepatitis C virus or anti-human immunodeficiency virus
             antibody

          -  Diagnosis of Churg-Strauss syndrome, Henoch-Sch√∂nlein purpura, rheumatoid vasculitis,
             mixed essential cryoglobulinaemia or systemic lupus erythematosus

          -  Circulating anti-GBM antibodies or linear IgG staining of the GBM on renal biopsy

          -  Life-threatening non-renal manifestations of vasculitis, including alveolar hemorrhage
             requiring mechanical ventilation within 24 hours of admission

          -  On dialysis for &gt; two weeks prior to entry

          -  Creatinine &gt; 200umol/l (2.3mg/dl) one year or more before entry

          -  A second clearly defined cause of renal failure

          -  Previous episode of biopsy-proven necrotising and/or crescentic glomerulonephritis

          -  &gt; two weeks treatment with cyclophosphamide or azathioprine

          -  &gt; 500mg IV methyl prednisolone

          -  Plasma exchange within the preceding year

          -  &gt; three months treatment with oral prednisolone

          -  Allergy to study medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels Rasmussen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Righospitalet, Copenhagen, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB22QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.vasculitis.org</url>
    <description>EUVAS homepage</description>
  </link>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2011</study_first_submitted>
  <study_first_submitted_qc>August 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2011</study_first_posted>
  <last_update_submitted>August 2, 2011</last_update_submitted>
  <last_update_submitted_qc>August 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2011</last_update_posted>
  <keyword>Vasculitis</keyword>
  <keyword>ANCA</keyword>
  <keyword>Therapy</keyword>
  <keyword>Plasma exchange</keyword>
  <keyword>Immunosuppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Microscopic Polyangiitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

